Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 3, 2015

Study Completion Date

May 3, 2015

Conditions
Facial RhytidesCrow's Feet LinesGlabellar LinesNasolabial Fold
Interventions
BIOLOGICAL

onabotulinumtoxinA

onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.

DRUG

bimatoprost ophthalmic solution 0.03%

bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.

DEVICE

JUVÉDERM® ULTRA XC

JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

DEVICE

JUVÉDERM® ULTRA PLUS XC

JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

DEVICE

JUVÉDERM® VOLUMA® XC

JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Trial Locations (1)

Unknown

Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02176356 - Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) | Biotech Hunter | Biotech Hunter